Application of CRISPR-Cas System in HPV Detection Using Biosensor Devices and POC Technologies

Chang He ¹

Yongqi Li ^{2, 3}

Jinkuan Liu ³

Li Zhu ^{4, 5}

Xue Li ^{6, 7}

Jeong-Woo Choi ^{8, 9}

Heng Li ^{10, 11}

Shan Liu ¹²

Chenzhong Li ¹³

Chen-Zhong Li ^{1, 7, 14}

Show full list: 10 authors

Hide authors affiliations

Biomedical Engineering, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China. |

School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China |

School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China. |

⁴

College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China |

⁵

College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. |

⁶

Juxintang (Chengdu) Biotechnology Co., Ltd., Tianfu Jincheng Laboratory, City of Future Medicine, Chengdu, 641400, China |

⁷

Juxintang (Chengdu) Biotechnology Co. Ltd., Chengdu 641400, China. |

⁸

Department of Chemical and Biomolecular Engineering, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea |

⁹

Department of Chemical and Biomolecular Engineering, Sogang University, Seoul 04107, Republic of Korea. |

¹⁰

Healton Animal Health Biotech Co., Ltd. Neijiang, 641000, China |

¹¹

Healton Animal Health Biotech Co. Ltd., Neijiang 641000, China. |

¹²

Sichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China. |

¹³

The Chinese University of Hong Kong - Shenzhen, HONG KONG |

¹⁴

Tianfu Jincheng Laboratory, City of Future Medicine, Chengdu 610072, China. |

Publication type: Journal Article

Publication date: 2025-01-01

American Association for the Advancement of Science (AAAS)

Journal: BME Frontiers

SJR: —

CiteScore: 7.1

Impact factor: 5

ISSN: 27658031

DOI: 10.34133/bmef.0114

Copy DOI

Abstract

Human papillomavirus (HPV) is the most common virus for genital tract infections. Cervical cancer ranks as the fourth most prevalent cancer globally, with over 99% of cases in women attributed to HPV infection. This infection continues to pose an ongoing threat to public health. Therefore, the development of rapid, high-throughput, and sensitive HPV detection platforms is important, especially in regions with limited access to advanced medical resources. CRISPR-based biosensors, a promising new method for nucleic acid detection, are now rapidly and widely used in basic and applied research and have received much attention in recent years for HPV diagnosis and treatment. In this review, we discuss the mechanisms and functions of the CRISPR-Cas system, focusing on its applications in HPV diagnostics. The review covers CRISPR technologies such as CRISPR-Cas9, CRISPR-Cas12, and CRISPR-Cas13, along with nucleic acid amplification methods, CRISPR-based signal output systems, and point-of-care testing (POCT) strategies. This comprehensive overview highlights the versatility and potential of CRISPR technologies in HPV detection. We also discuss the numerous CRISPR biosensors developed since the introduction of CRISPR to detect HPV. Finally, we discuss some of the challenges faced in HPV detection by the CRISPR-Cas system.